Popular terms

Gly topics
Door Assembly
Swimming Goggles
Transverse
Alkoxylate
Fluoropolymer
Air Cleaning
Rotor Shaft
Aspect Ratio
Disconnect
Synchronization
Remote Control
Ethylene Glycol
Surfactant
Combustion
Steviol Glycosides

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Gly patents



      

This page is updated frequently with new Gly-related patent applications.




Date/App# patent app List of recent Gly-related patents
02/04/16
20160036082 
 Cross-linked polymer electrolyte membranes patent thumbnailCross-linked polymer electrolyte membranes
Crosslinked polymers are produced by polymerizing a styrene-based comonomer with a bifunctional styrenated crosslinkable monomer comprising the following straight chain formula: ch2═ch—c6h4—ch2—(och2ch2)n-o—ch2—c6h4—ch═ch2. The styrenated crosslinkable monomer can be produced from a two arm polyethylene glycol having a molecular weight between 200 g/mol and 35,000 g/mol.
Nissan North America, Inc.


02/04/16
20160033532 
 Mammalian protein co-recognition by broadly neutralizing antibodies as modified immunogens for re-elicitation patent thumbnailMammalian protein co-recognition by broadly neutralizing antibodies as modified immunogens for re-elicitation
The present invention relates to using hiv-1 broadly neutralizing antibodies to screen for glycan-dependent or protein-dependent self reactivities inherent in these mutated antibodies, and defining this cross recognition at the molecular level, and utilizing the information to re-elicit trimer-specific and/or n-glycan-dependent or protein-surface-dependent broadly neutralizing antibodies and therapeutic applications thereof.. .
The Scripps Research Institute


02/04/16
20160032401 
 Glycine, mitochondrial one-carbon metabolism, and cancer patent thumbnailGlycine, mitochondrial one-carbon metabolism, and cancer
Methods of treatment, diagnosis, and determining prognosis of subjects with cancer, generally comprising determining levels of glycine metabolism or a mitochondrial 1-carbon (1-c) pathway enzyme, e.g., shmt2, mthfd1l, or mthfd2, and optionally administering an antifolate or an agent that inhibits a mitochondrial 1-carbon (1-c) pathway enzyme, e.g., shmt2 or mthfd2.. .
The General Hospital Corporation


02/04/16
20160032344 
 Polysialic acid, blood group antigens and glycoprotein expression in prokaryotes patent thumbnailPolysialic acid, blood group antigens and glycoprotein expression in prokaryotes
The invention described herein generally relates to glycoengineering host cells for the production of glycoproteins for therapeutic use. Host cells are modified to express biosynthetic glycosylation pathways.
Glycobia, Inc.


02/04/16
20160032332 
 Variant thioesterases and methods of use patent thumbnailVariant thioesterases and methods of use
The present invention relates to variant thioesterases and their use in plants, e.g., to increase enzymatic activity and to promote increased production of mid-chain length fatty acids (e.g., 8 to 14 carbons) and at desired ratios. Further disclosed herein are methods of manufacturing renewable chemicals through the manufacture of novel triglyceride oils followed by chemical modification of the oils.
Solazyme, Inc.


02/04/16
20160032218 
 Fatty amines, amidoamines, and their derivatives from natural oil metathesis patent thumbnailFatty amines, amidoamines, and their derivatives from natural oil metathesis
Fatty amine compositions made from a metathesis-derived c10-c17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives are disclosed. In another aspect, fatty amidoamines made by reacting a metathesis-derived c10-c17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with an aminoalkyl-substituted tertiary amine are disclosed.
Stepan Company


02/04/16
20160032217 
 Fragrance composition patent thumbnailFragrance composition
(b) at least one a solvent selected from the group consisting of benzylalcohol, benzylbenzoate, diethylphthalate, dipropylene glycol, ethyl alcohol, iso-propyl myristate, triethylcitrate, downol dpm, isopar l, triacetine and their mixtures.. .

02/04/16
20160032128 
 Coating composition based on coloring foodstuffs patent thumbnailCoating composition based on coloring foodstuffs
A coating composition includes, in relation to 100% of the weight thereof: between 10 and 90 wt. % of at least one film-forming polymer selected from cellulosic polymers or derivatives of cellulosic polymers, derivatives of vinyl alcohol, derivatives of vinyl pyrrolidones, polymers of a natural origin, acrylic or methacrylic derivatives, derivatives of glycol or propylene glycol or combinations of the two substances or the copolymers of vinyl alcohol and polyethylene glycol (peg); between 1 and 50 wt.
Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic


02/04/16
20160032105 
 Blue colorant and  making thereof patent thumbnailBlue colorant and making thereof
Is provided where r1 and r2 are formed by the combination of cinnamic acid and glucose and r3 is malonyl glycoside. When used as blue colorant in food, the blue colorant provides stable blue shade at low ph levels and possesses good heat and light stability..

02/04/16
20160032081 
 Polyvinyl alcohol aqueous solution patent thumbnailPolyvinyl alcohol aqueous solution
The present invention provides a polyvinyl alcohol aqueous solution capable of suppressing contamination by components other than polyvinyl alcohol to form a film that contains few air bubbles and is excellent in adhesion to a base material, and a laminated film formed of the polyvinyl alcohol aqueous solution. The present invention relates to a polyvinyl alcohol aqueous solution including polyvinyl alcohol, a surface tension regulator, and water, the surface tension regulator being at least one selected from the group consisting of a polyether silicone compound, a glycerol compound, a cyclic hydrocarbon compound, a propylene glycol compound, and a fatty acid ester compound, the polyvinyl alcohol aqueous solution containing 500 to 10000 parts by weight of water based on 100 parts by weight of the polyvinyl alcohol and having a surface tension of 45 to 72 mn/m..
Sekisui Chemical Co., Ltd.


02/04/16
20160032049 

Branched polymers


The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate.
Nektar Therapeutics


02/04/16
20160032010 

Method for preparing glycan-hydrolyzed antibody, and homogeneous glycosylated antibody


The present invention is aimed to provide a method for preparing an acceptor that is n-glycan hydrolyzed antibody or a fc fragment thereof used for producing antibody having a homogeneous n-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring n-glycans linked to an antibody. The present invention is directed to a method for producing a n-glycan hydrolyzed antibody or fc fragment thereof, comprising reacting the antibody or the fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective n-glycan with a desired structure linked to an antibody or a fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc..
Immuno-biological Laboratories Co., Ltd.


02/04/16
20160032007 

Human antibody fragments against chondroitin sulfate proteoglycan 4 (cspg4)


Human antibody fragments against chrondroitin sulfate proteoglycan 4 can be used to deliver cytotoxic agents to cells which express cspg4. The agents can be diagnostic or therapeutic moieties.
Duke University


02/04/16
20160031923 

Glycoside derivatives, preparation thereof and use thereof as prosthetic groups


The present invention relates to glycoside-derived compounds, to the processes for preparing same and to the use thereof as prosthetic groups for radiolabelling biomolecules. These compounds are co-azido-alkyl 6-deoxy-6-[18f]-fluoroglycosides of formula (i), in which: k is equal to 2 or 3; n is an integer between 1 and 5; r is independently h or a c1-c5 alkyl group, m being an integer between 0 and 2 if k=2 and m between 0 and 3 if k=3; and x is chosen from the group comprising o, s, ch2 and nr′, in which r′ is independently a c1-c5 alkyl group or an aryl group, including all the stereoisomers thereof..
Centre National De La Recherche Scientifique - Cnrs


02/04/16
20160031864 

Aromatic monomers deriving from glycerol units, process for their preparation and use thereof for the preparation of water-soluble conjugated polymers


Monomers having formula (i) and process for their synthesis which comprises the etherification reaction of a halogen-derivative (z═cl, br, i) having formula (iii) with the hydroxyl group of the glycerol derivative (iv), according to the following scheme:. .
Eni S.p.a.


02/04/16
20160031816 

Aryl dihydropyridinones and piperidinone mgat2 inhibitors


Or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (mgat2) inhibitors which may be used as medicaments..

02/04/16
20160031801 

Deuterated 2-amino-3-hydroxypropanoic acid derivatives


This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an nmda glycine-site antagonist..
Concert Pharmaceuticals, Inc.


02/04/16
20160031794 

Organic oligomers of acylglycerol


Organic oligomers of acylglycerol having general formula (i): formula (i), in which m1 and q1 are organic groups; g11 is a hydroxylpropyl group; g12 and g13 are α/α′-acylglycerols; n is a natural integer from the range [0; 8]; m is a natural integer from the range [0; 4]; and p is a natural integer from the range [0; 3].. .
Institut National De La Recherche Agronomique


02/04/16
20160031779 

Production of propylene glycol monoalkyl ether


Processes for producing propylene glycol monoalkyl ether are described herein and include contacting propylene oxide and an alcohol in the presence of an alkali or alkaline earth metal alkoxide catalyst to produce an alkoxylation mixture including propylene glycol monoalkyl ether; distilling the alkoxylation mixture to produce a first overhead stream including propylene oxide and the alcohol and a first bottoms stream including propylene glycol monoalkyl ether; distilling the first bottoms stream to produce a second overhead stream including purified propylene glycol monoalkyl ether and a second bottoms stream including heavier byproducts; further distilling the second bottoms stream to form a resulting bottoms stream including caustic and heavier byproducts; introducing an alkali metal borohydride into at least a portion of the resulting bottoms stream to form an alkali metal borohydride containing stream; and introducing the alkali metal borohydride containing stream into one or more distillations upstream of recovery of the second overhead stream.. .
Lyondell Chemical Technology, L.p.


02/04/16
20160031777 

Process for the selective production of propanols by hydrogenation of glycerol


The present invention discloses a process for the selective hydrogenation of glycerol in the liquid phase to produce 1- and 2-propanols in high yields as the major organic products. The process comprises subjecting a glycerol stream having at least 30% by weight water to a combination of low pressure and high temperature hydrogenation conditions in the presence of a promoted or un-promoted skeletal copper catalyst..
W. R. Grace & Co.-conn.


02/04/16
20160031767 

Photoactive energetic materials


Energetic materials that are photoactive or believed to be photoactive may include a conventional explosive (e.g. Petn, nitroglycerine) derivatized with an energetic uv-absorbing and/or vis-absorbing chromophore such as 1,2,4,5-tetrazine or 1,3,5-triazine.
Los Alamos National Security, Llc.


02/04/16
20160031764 

Use of acylated carbonic esters of glycerol in agriculture


A process for treating plants, including the application of at least one compound, termed carbonic ester of glycerol, including at least one carboxylic ester function formed by a carbonic acid-derived group and at least one glycerol-derived group, with the exception of cyclic glyceryl carbonate including five ring members.. .
Institut National De La Recherche Agronomique


02/04/16
20160030929 

Method for preparing catalyst for glycerin dehydration, and preparing acrolein


The present invention relates to a method for preparing a catalyst for glycerin dehydration, a catalyst for glycerin dehydration prepared thereby, and a method for preparing acrolein. More particularly, the catalyst for glycerin dehydration prepared by the preparation method is able to minimize by-product formation to improve acrolein selectivity and to maintain high catalytic activity during the reaction..
Lg Chem, Ltd.


02/04/16
20160030587 

Conjugates of an anti-tnf-alpha antibody


Conjugates of an anti-tnf antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof.
Nektar Therapeutics


02/04/16
20160030585 

Novel fatty acids and their use in conjugation to biomolecules


Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

02/04/16
20160030581 

Biodegradable drug delivery compositions


A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.. .
Medincell


02/04/16
20160030580 

Topical dapsone and dapsone/adaplene compositions and methods for use thereof


Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder.
Allergan, Inc.


02/04/16
20160030572 

Liquid formulations


Disclosed is a concentrate for dilution comprising a s1p receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow..
Novartis Ag


02/04/16
20160030569 

Low-glycerin formulations for hiv treatment and prevention


The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (nrtis), preferably [2-(6-amino-pur: in-9-yl)-1-methyl-ethoxymethy]-phosphonic acid (tenofivir, pmpa), or a physiologically functional derivative thereof, wherein the formulations contain a low level of glycerin. Human immunodeficiency vims (hiv) infection and related diseases are a major public health problem worldwide.
Conrad


02/04/16
20160030449 

Transdermal cream


This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene.
Therapeuticsmd, Inc.


02/04/16
20160030402 

Sustained-release nanoparticle compositions and methods for using the same


The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an n-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (peg) conjugate and a method for using the same in the treatment or prevention of a disease or condition.. .
Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical


02/04/16
20160030391 

Methods and compositions for improving cognitive function


This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (cns) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2a (sv2a) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (cns) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, mild cognitive impairment (mci), amnestic mci (amci), age-associated memory impairment (aami), age related cognitive decline (arcd), dementia, alzheimer's disease (ad), prodromal ad, post traumatic stress disorder (ptsd), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, parkinson's disease (pd), autism, compulsive behavior, and substance addiction..
The Johns Hopkins University


02/04/16
20160030385 

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions


The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh


02/04/16
20160030375 

Glycogen or polysaccharide storage disease treatment method


A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.. .
Baylor Research Institute


02/04/16
20160030370 

Methods of intravenous administration of glyburide


The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.. .
Remedy Pharmaceuticals, Inc.


02/04/16
20160030339 

Treatment of diabetes mellitus by long-acting formulations of insulins


The application relates to an aqueous pharmaceutical formulation for use in the treatment of type i or type ii diabetes mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 u/ml [equimolar to 200-1000 iu human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 u/ml of insulin glargine.. .
Sanofi


02/04/16
20160030319 

Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine


Provided are compositions, e.g., oral and personal care products, comprising (i) a tetrabasic zinc-amino acid or trialkyl glycine-halide complex, and (ii) cysteine in free or in orally or cosmetically acceptable salt form, together with methods of making and using the same.. .
Colgate-palmolive Company


02/04/16
20160030313 

Cosmetic composition


A finisher composition in the form of an oil-in-water emulsion. The continuous aqueous phase of the emulsion is from about 20 to 85 wt % of water.
The Procter & Gamble Company


02/04/16
20160030300 

Multi-step regimen for improving the appearance and feel of human skin


A method of improving the look and feel of skin by using a two-step regimen that includes applying an underlying layer of a skin care composition and applying an overlying layer of a finisher composition on top of the underlying skin care composition layer. The finisher composition is an oil-in-water emulsion comprising a continuous aqueous phase, a dispersed oil phase, and from 10 to 25 wt % of substantially spherical particles.
The Procter & Gamble Company


02/04/16
20160029681 

Method of enhancing bioavailability of dha and other lipid-soluble nutrients


A method of enhancing the bioavailability of a lipid-soluble nutrient, such as dha, arachidonic acid, tocopherol, and carotenoids, in a newborn or preterm infant is disclosed. In this method, the lipid-soluble nutrient is administered in a nutritional product (such as an infant formula) to a preterm or newborn infant.
Abbott Laboratories


02/04/16
20160029677 

Novel glucosyl steviol glycosides, their compositions and their purification


Novel glucosylated steviol glycosides and their purification are provided herein. In addition, compositions comprising said novel glucosylated steviol glycosides and methods of preparing and using the same are provided..
The Coca-cola Company


01/28/16
20160025742 

Synthesis and use of isotopically-labelled glycans


Isotopically-labelled glycans and their synthesis and use as internal standards in the analysis by mass spectrometry of glycan mixtures is described. The methods of synthesis described herein may be used conveniently to prepare libraries of heavy glycans for use in the qualitative and quantitative identification of glycans in natural samples..
AsociaciÓn Centro De InvestigaciÓ Cooperativa En Biomateriales


01/28/16
20160025734 

Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate


The disclosure provides methods to facilitate the diagnosis of prostate cancer. In particular, the methods disclosed herein can be used to distinguish prostate cancer from benign prostatic hyperplasia.
The Brigham And Women's Hospital, Inc.


01/28/16
20160024554 

Rapid, low-sample-volume cholesterol and triglyceride assays


Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates.
Theranos, Inc.


01/28/16
20160024553 

Measurement human pancreatic lipase activity


A measurement method for human pancreatic lipase activity in a sample, includes a contact step of bringing a bile acid that makes a ph for giving a maximum value of human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at ph 7.4 or lower; and a detection step of detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample, and the bile acid is a bile acid containing: one of or two or more of a-type bile acids selected from the group consisting of gdca, gcdca, tdca, tcdca and salts thereof; and/or a combination of one of or two or more of b-1-type bile acids selected from the group consisting of gca, gudca, tca, tudca and salts thereof, and one of or two or more of b-2-type bile acids selected from the group consisting of dca, cdca and salts thereof.. .
Asahi Kasei Pharma Corporation


01/28/16
20160024538 

Hydroxylated triacylglycerides


Methods and compositions for the production of food compositions, oils, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-acp synthase enzyme, a fatty acyl-acp thioesterase, a fatty acyl-coa/aldehyde reductase, a fatty acyl-coa reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing food compositions, and transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants..
Solazyme, Inc.


01/28/16
20160024497 

Compositions and methods for inhibiting expression of gsk-3 genes


The invention relates to a double-stranded ribonucleic acid (dsrna) targeting glycogen synthase kinase-3 (gsk-3), and methods of using the dsrna to inhibit expression of gsk-3.. .
Alnylam Pharmaceuticals, Inc.


01/28/16
20160024443 

Laundry scent additive


A laundry scent additive having polyethylene glycol and perfume. The laundry scent additive enables consumers to control the amount of scent imparted to their laundry..
The Procter & Gamble Company


01/28/16
20160024438 

Cleaning solution and methods of cleaning a turbine engine


A cleaning solution for a turbine engine includes water within a range between about 68.65 percent and about 99.63 percent by volume of the cleaning solution; a first organic acidic component within a range between about 0.1 percent and about 15 percent by volume of the cleaning solution; wherein the organic acid comprises citric acid; a second organic acidic component within a range between about 0.1 percent and about 15 percent by volume of the cleaning solution; wherein the organic acid comprises glycolic acid; isoropylamine sulphonate within a range between about 0.07 percent and 0.14 percent by volume of the cleaning solution; alcohol ethoxylate within a range between about 0.035 percent and 0.07 percent by volume of the cleaning solution; triethanol amine within a range between about 0.035 percent and 0.07 percent by volume of the cleaning solution; sodium lauriminodipropionate within a range between about 0.03 percent and 1.0 percent by volume of the cleaning solution. The cleaning solution has a ph value in the range between about 2.5 and about 7.0..
General Electric Company


01/28/16
20160024422 

Bioderived biodegradable lubricant


A multi-purpose lubricant is described. In accordance with one implementation, a lubricant comprises food grade based oils substantially complying with usda h-1 specifications for incidental contact with food, wherein at least one oil is selected from the group consisting of food grade plant oil, food grade poly-alpha-olefin, polyalkylene glycol, and mixtures thereof.

01/28/16
20160024408 

One-pot process for the production of biodiesel and glycerol ether mixtures useful as biofuels


R is h or a tertiary alkyl group, wherein the reaction takes place in the presence of an acid transesterification catalyst by irradiation with microwaves and/or ultrasound and/or radio waves.. .

01/28/16
20160024307 

Use of polycarboxylate ethers in combination with other additives for milling cement


Use of an aqueous composition containing at least one polycarboxylate ether as cement grinding aid, wherein the aqueous composition contains one or more additives, or the aqueous composition is used in combination with one or more additives, and wherein the additive is selected from 1,3-propanediol, a carboxylic acid, a sulfonated amino alcohol, boric acid, a salt of boric acid, a salt of phosphoric acid, sorbitol, a saccharide, a gluconate, iron sulfate, tin sulfate, an antimony salt, an alkali salt, an alkaline earth salt, lignin sulfonate, glycerol, melamine, melamine sulfonate and mixtures thereof.. .
Sika Technology Ag


01/28/16
20160024298 

Resin composition and resin molded article


A resin composition includes a polylactic acid resin, an alloy resin of a polycarbonate resin and an acrylonitrile-butadiene rubber-styrene resin, surface-coated red phosphorus whose surface is coated with a hydrophobic resin, and a glycerol fatty acid ester plasticizer, wherein an average coating thickness of the polylactic acid resin and the alloy resin that cover the surface-coated red phosphorus, which is obtained by observing a structure inside a molded article with a tem in the case of forming the molded article, is 100 nm or more.. .
Fuji Xerox Co., Ltd.


01/28/16
20160024185 

Identification of antibodies specific for lyssaviruses and methods of their use


Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as rabv, mokv and wcbv) and/or specifically bind recombinant glycoprotein from different lyssaviruses..
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


01/28/16
20160024118 

Copper (i) complexes with glycine, pyruvate, and succinate


The present invention is directed to a pharmaceutical and/or dietary supplement composition comprising an effective amount of a copper (i) complex with glycine, pyruvate, or succinate and methods of treating mitochondrial, neuromuscular, and other diseases. Also provided are pharmaceutical treatment regimes and kits comprising a copper (i) complex with glycine, pyruvate, or succinate..
C Lab Pharma International, S.a.


01/28/16
20160024108 

Use of dithiine-tetracarboximides for controlling bacterial harmful organisms in useful plants


The present invention relates to the use of dithiine-tetracarboximides of formula (i) for controlling selected bacterial harmful organisms in useful plants, wherein the bacterial harmful organisms are selected from the group consisting of acidovorax avenae, burkholderia spec., burkholderia glumae, candidatus liberibacter spec., candidatus liberibacter asiaticus, corynebacterium, erwinia spec. (dickeya, pectobacterium carotovorum, erwinia amylovora), pseudomonas syringae, pseudomonas syringae pv.
Bayer Cropscience Aktiengesellschaft


01/28/16
20160024063 

Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient


The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating gpr40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs.
Hyundai Pharm Co., Ltd


01/28/16
20160024003 

Quaternized fatty amines, amidoamines and their derivatives from natural oil metathesis


Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amines, wherein the fatty amine is made by reducing the amide reaction product of of a metathesis-derived c10-c17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and a secondary amine, are disclosed. Quaternary ammonium, betaine, or sulfobetaine compositions derived from fatty amidoamines, wherein the amidoamine is made by reacting of a metathesis-derived c10-c17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives and an aminoalkyl-substituted tertiary amine, are also disclosed.
Stepan Company


01/28/16
20160023989 

Esteramines and derivatives from natural oil metathesis


Esteramine compositions and their derivatives are disclosed. The esteramines comprise a reaction product of a metathesis-derived c10-c17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with a tertiary alkanolamine.
Stepan Company


01/28/16
20160023977 

System for removing salt from a rich mono ethylene glycol stream


A system for, and method of, recovering salt from fluid stream in a recycle loop of a flash separator has a desanding hydrocyclone located in the hot recycle loop of the flash separator; a first solids fluidization device located at the bottom end of the flash separator's brine column; a second desanding hydrocyclone arranged to receive a salt slurry stream created by the first solids fluidization device; and an accumulator located downstream of the second desanding hydrocyclone and having a second solids fluidization device located at its bottom end. Each solids fluidization device causes a motive fluid to exit the device in a swirling motion to fluidize the salt components contained in the resident fluid.
Cameron Solutions Inc.


01/28/16
20160023189 

Diethyl oxalate catalysts


A highly effective catalyst for the preparation of diethyl oxalate using carbon monoxide using pd/α-al2o3 and ceo2 as a promoter. High conversion rates with greatly extended catalyst life is achieved with the ceo2-enhanced pd catalysts.
University Of Wyoming


01/28/16
20160022899 

Diabetes regulator


An implantable device that continuously regulates the blood glucose levels of a type 1 diabetes mellitus patient is provided. The device which is implanted in the bloodstream, relies on a microfluidic chip and a microsieve that efficiently separate leukocytes away from an amount of blood received and an islet compartment made up of multiple islets (beta and alpha cells) from at least one compatible donor pancreas source.

01/28/16
20160022878 

Method of treating pleural abnormality


The invention relates to a method of treating pleural abnormalities in a subject in need thereof, comprising the steps of: (a) attaching a biodegradable polymeric membrane onto a pleural wound to elicit fibronectin from fibroblasts to cause fibrous adhesion; and (b) securing the membrane with securement products, including sutures, staples, and sealants. The present invention also relates to a biodegradable adhesion membrane used for treating pleural abnormalities, comprising: a biodegradable base material selected from the group consisting of polycaprolactone (pcl), polylactic acid or polylactide (pla), polyhydroxybutyrate (phb), poly(ethylene adipate), poly(butylene adipate) (pba), chitosan, hyaluronic acid, and polyglycolic acid (pga); wherein the thickness of the membrane is 0.1-1 mm..
National Taiwan University


01/28/16
20160022830 

Methods for preparing polymeric reagents


The present invention provides among other things methods for preparing polymeric reagents, wherein the method comprises (a) providing an aromatic moiety bearing a hydroxy group, a first amino group and a second amino group; (b) reacting a functional group reagent with the hydroxy group to result in a hydroxy group bearing a functional group capable of reacting with an amino group of an active agent and resulting in a hydolyzable carbamate; and (c) reacting a plurality of poly(alkylene glycol) water-soluble polymers bearing a reactive group with the first amino group and second amino group to result in (i) a first amino group bearing a water-soluble polymer through a spacer moiety, and (ii) a second amino group bearing a second water-soluble polymer through a spacer moiety.. .
Nektar Therapeutics


01/28/16
20160022826 

Carbohydrate-modified glycoproteins and uses thereof


The present invention provides immunogenic compounds which stimulate immune responses in a subject. The present invention provides compositions comprising an isolated glycoprotein antigen covalently bound at pre-existing carbohydrate residues present on the glycoprotein to a carbohydrate epitope.
Newlink Genetics Corporation


01/28/16
20160022823 

Albumin conjugated temperature and ph-sensitive multi-block copolymer, a preparation thereof and drug delivery system using the same


The present invention relates to a conjugate of albumin and a temperature- and ph-sensitive multi-block copolymer, a method of preparation thereof, and a sustained-release drug carrier comprising the same, and more specifically, to a conjugate in which polyethylene glycol-poly(amino urethane) (peg-pau) or polyethylene glycol-poly(amino ester urethane) (peg-paeu) multi-block copolymer is conjugated to albumin, a method of preparing the same, and a long-term sustained-release drug carrier comprising the same, capable of reducing an initial burst release of drugs and improving an affinity to drugs.. .
Research & Business Foundation Sungkyunkwan University


01/28/16
20160022820 

Transdermal delivery system


A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the c6 to c30 aliphatic ester of salicylic acid and (ii) polyethylene glycol (peg) of average molecular weight no more than 300.. .
Acrux Dds Pty Ltd.


01/28/16
20160022783 

Polyalkylene oxide valerate hemoglobin conjugates


The present invention relates generally to polyethylene glycol (peg) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and n-terminal valines of the hemoglobin.. .
Sangart, Inc.


01/28/16
20160022781 

Methods for administering hypoglycemic agents


The present invention relates to methods of administering hypoglycemic agents and/or glp-1 agonists.. .
Glaxosmithkline Llc


01/28/16
20160022770 

Use of glycomacropeptide to improve women's health


Gmp-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.. .

01/28/16
20160022762 

Agent for eliminating multidrug resistance


The invention belongs to medicine, namely to pharmacology, and may be used to overcome multiple drug resistance in oncological and infectious patients undergoing long-term chemotherapy. Essence of the invention: proposed herein as a therapeutic agent intended to overcome multiple drug resistance is a hexapeptide with the following structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine..

01/28/16
20160022755 

Herbal gel from chestnut seed coat for pelvic floor muscle relaxation in women and a synthesizing the same


The embodiments herein disclose a method for extracting the herbal extract from acorn or oak nut of quercus brantii for synthesizing a herbal gel for targeting a vaginal relaxation syndrome (vrs) and a pelvic organ prolapsed (pop). The acorn or oak nut from quercus brantii trees is collected.

01/28/16
20160022629 

Sublingual spray formulation comprising dihydroartemesinin


The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions..
Londonpharma Limited


01/28/16
20160022578 

Polypeptide based block copolymer and the process for the preparation thereof, and the polymer micelles using the same


The present disclosure relates to a polypeptide based block copolymer having biodegradability due to peptidase, and a process for the preparation thereof, and polymer micelles using the same. The block copolymer according to the present disclosure is a block copolymer of a polyethylene glycol-based compound having properties such that the solubility for water is different depending on the ph, but cannot form micelles due to a self-assembly phenomenon; and a polyglutamic acid-based compound formed using an aminolysis reaction of glutamic acid and tertiary amine in which the end of one alkyl group is substituted with nh2, or using an aminolysis reaction of glutamic acid and triamine.
Research & Business Foundation Sungyunkwan University


01/28/16
20160022567 

Waxes having oil-in-water self-emulsifying and water gel-forming properties, compositions, uses and methods relating to same


The present invention relates to waxes useful for cosmetic applications having stable oil-in-water emulsion-forming properties and, in some embodiments, stable gel-in-water-forming properties. In some embodiments, the waxes exhibit self-emulsifying properties, and can be produced without the addition of any other substances to achieve the emulsion (e.g., co-emulsifiers, hydrophilic polymers, polar surfactants, rheological modifiers, gelling agents).
Intelactive S.a.


01/28/16
20160022557 

Alkyl glycoside-based micellar thickeners for surfactant systems


A rheology modifier which includes a mixture of short and long chain fatty acid esters is suitable for use in liquid surfactant-based compositions. A surfactant-based composition includes a surfactant, the rheology modifier, and water.
Lubrizol Advanced Materials, Inc.


01/28/16
20160022479 

Externally heated thermal pack


An improved, externally heated thermal pack, has an enclosure or bladder comprised of a skin of a durable flexible film, and has a fill of a blend of propylene glycol (mono- or poly-), water, and a superabsorbent cross-linked polyacrylic salt. The fill is hermetically sealed within the enclosure or bladder.
Normedical Group As


01/28/16
20160022221 

Sensor fault detection using analyte sensor data pattern comparison


Analyte sensor faults are detected. Datasets of glucose values sensor electronics are coupled to a glucose sensor in fluid contact with interstitial fluid under a skin surface.
Abbott Diabetes Care Inc.




Gly topics: Door Assembly, Swimming Goggles, Transverse, Alkoxylate, Fluoropolymer, Air Cleaning, Rotor Shaft, Aspect Ratio, Disconnect, Synchronization, Remote Control, Ethylene Glycol, Surfactant, Combustion, Steviol Glycosides

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Gly for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gly with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2332

4924

0 - 1 - 104